BR112017015310A2 - uso de pgr4 como um agente anti-inflamatório - Google Patents

uso de pgr4 como um agente anti-inflamatório

Info

Publication number
BR112017015310A2
BR112017015310A2 BR112017015310A BR112017015310A BR112017015310A2 BR 112017015310 A2 BR112017015310 A2 BR 112017015310A2 BR 112017015310 A BR112017015310 A BR 112017015310A BR 112017015310 A BR112017015310 A BR 112017015310A BR 112017015310 A2 BR112017015310 A2 BR 112017015310A2
Authority
BR
Brazil
Prior art keywords
pgr4
inflammatory agent
inflammatory
lubricin
translocation
Prior art date
Application number
BR112017015310A
Other languages
English (en)
Other versions
BR112017015310A8 (pt
Inventor
Chodobska Adam
d sullivan Benjamin
R Truitt Edward
D Jay Gregory
Fareed Jawed
Szmydynger-Chodobska Joanna
Elsaid Khaled
Krawetz Roman
Avery Schmidt Tannin
Original Assignee
Lubris Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lubris Llc filed Critical Lubris Llc
Publication of BR112017015310A2 publication Critical patent/BR112017015310A2/pt
Publication of BR112017015310A8 publication Critical patent/BR112017015310A8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Dermatology (AREA)
  • Neurology (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Communicable Diseases (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Cardiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Obesity (AREA)
  • Ophthalmology & Optometry (AREA)
  • Tropical Medicine & Parasitology (AREA)

Abstract

são descritos métodos de uso da glicoproteína prg4, também conhecida como lubricina, para reduzir, inibir ou regular negativamente vias pró-inflamatórias em pacientes em risco de sofrer uma resposta inflamatória ou sintoma de alergia através do antagonismo a cd44, regulando a produção de citocina pró-inflamatória, inibindo a translocação de nf-¿b e/ou facilitar a remoção de restos celulares ou de matriz ou de alérgenos que induzem a inflamação.
BR112017015310A 2015-01-26 2016-01-26 uso de pgr4 como um agente anti-inflamatório BR112017015310A8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562107799P 2015-01-26 2015-01-26
US201562273059P 2015-12-30 2015-12-30
PCT/US2016/014952 WO2016123123A1 (en) 2015-01-26 2016-01-26 Use of prg4 as an anti-inflammatory agent

Publications (2)

Publication Number Publication Date
BR112017015310A2 true BR112017015310A2 (pt) 2018-01-16
BR112017015310A8 BR112017015310A8 (pt) 2021-02-23

Family

ID=55361962

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112017015310A BR112017015310A8 (pt) 2015-01-26 2016-01-26 uso de pgr4 como um agente anti-inflamatório

Country Status (21)

Country Link
US (2) US10967048B2 (pt)
EP (2) EP3718559A1 (pt)
JP (2) JP6758299B2 (pt)
KR (1) KR20170123619A (pt)
CN (2) CN113908257A (pt)
AU (2) AU2016211694B2 (pt)
BR (1) BR112017015310A8 (pt)
CA (1) CA2972817A1 (pt)
CL (2) CL2017001893A1 (pt)
EA (1) EA036291B1 (pt)
ES (1) ES2808199T3 (pt)
HK (1) HK1247834A1 (pt)
IL (2) IL253596B (pt)
MA (1) MA53108A (pt)
MX (1) MX2017009723A (pt)
PH (1) PH12017501323A1 (pt)
RU (1) RU2017129880A (pt)
SG (2) SG10201809947UA (pt)
TN (1) TN2017000270A1 (pt)
WO (1) WO2016123123A1 (pt)
ZA (1) ZA201705378B (pt)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015060935A1 (en) 2013-10-22 2015-04-30 Lubris, Llc Control of rheological properties of mixed hyaluronate/lubricin solutions
EP4062924A1 (en) 2013-11-26 2022-09-28 Lubris LLC Compositions and methods for inhibiting intercellular interactions
ES2808199T3 (es) 2015-01-26 2021-02-25 Lubris Llc Uso de PRG4 como un agente antiinflamatorio
EP3288406A4 (en) 2015-05-01 2018-12-26 Gentex Corporation Helmet impact attenuation article
HUE056409T2 (hu) 2015-05-19 2022-02-28 Lubris Llc PRG4 alkalmazása dinamikus látásélesség és magasabb rendû aberrációk javítására
CN106215170A (zh) * 2016-08-23 2016-12-14 重庆医科大学 白细胞介素36α在制备治疗、诊断或预防脓毒症药物中的用途
US10806581B2 (en) 2017-05-23 2020-10-20 Harmony Development Group, Inc. Tethered implantable device having an apical base plate with a hydraulic intracardiac adjusting mechanism
US10940002B2 (en) 2017-06-28 2021-03-09 Harmony Development Group, Inc. Force transducting inflatable implant system including a dual force annular transduction implant
WO2019173385A1 (en) 2018-03-05 2019-09-12 Harmony Development Group, Inc. A force transducting implant system for the mitigation of atrioventricular pressure gradient loss and the restoration of healthy ventricular geometry
CN108795867A (zh) * 2018-06-05 2018-11-13 华东理工大学 用于构建结肠癌细胞腹膜转移体外三维模型的方法
JP2021527645A (ja) * 2018-06-21 2021-10-14 ルブリス，エルエルシー． 創傷治癒での使用のためのラブリシン
CN109125709B (zh) * 2018-08-23 2021-10-22 成都华创生物技术有限公司 Trail突变体在制备治疗痤疮药物中的应用及一种制剂
CN109620952A (zh) * 2019-01-04 2019-04-16 北京中台恒基生物技术有限公司 一种肿瘤疫苗及其制备方法
WO2020150390A1 (en) * 2019-01-15 2020-07-23 Cornell University Recombinant mucins, and compositions and methods for using the same
US20220298234A1 (en) * 2019-05-13 2022-09-22 The Johns Hopkins University Macrophage diversity in regenerative, fibrotic biomaterial environments
CN114173805A (zh) * 2019-06-03 2022-03-11 卢布里斯有限责任公司 Prg4治疗癌症的用途
WO2022010996A1 (en) * 2020-07-07 2022-01-13 University Of Connecticut Method and composition for reducing or preventing bone resorption
IT202000022636A1 (it) * 2020-09-25 2022-03-25 Ente Ospedaliero Specializzato In Gastroenterologia Istituto Nazionale Di Ricovero E Cura A Caratter “terapia di combinazione di sorafenib e/o regorafenib con la proteina ricombinante umana proteoglicano-4 per il trattamento dell'epatocarcinoma”
CN114184792B (zh) * 2021-11-17 2024-05-28 中国人民解放军总医院第二医学中心 冠心病标志物il-29及其应用

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6433142B1 (en) 1989-08-08 2002-08-13 Genetics Institute, Llc Megakaryocyte stimulating factors
US6960562B2 (en) 1999-04-23 2005-11-01 Rhode Island Hospital, A Lifespan Partner Tribonectin polypeptides and uses thereof
US6743774B1 (en) 1999-04-23 2004-06-01 Rhode Island Hospital Tribonectins
US7001881B1 (en) 1999-04-23 2006-02-21 Rhode Island Hospital Tribonectins
US20020006665A1 (en) 2000-04-05 2002-01-17 D'elia John Ketogulonigenium endogenous plasmids
US7415381B2 (en) 2003-01-09 2008-08-19 Rhode Island Hospital, A Lifespan Partner Joint friction sensing
WO2005000331A2 (en) 2003-06-04 2005-01-06 Mucosal Therapeutics, Inc. Compositions for the treatment and prevention of degenerative joint disorders
CN102924584A (zh) * 2003-08-14 2013-02-13 惠氏公司 重组润滑素分子及其用途
US20090155200A1 (en) 2004-04-20 2009-06-18 Jay Gregory D Methods of promoting cartilage healing or cartilage integration
US20080287369A1 (en) 2004-07-23 2008-11-20 Jay Gregory D Compositions and Methods for Viscosupplementation
EP1827478A4 (en) 2004-12-03 2009-08-05 Mucosal Therapeutics Llc METHODS OF TREATING JOINED OR SICK JOINTS
US20070111327A1 (en) 2005-05-05 2007-05-17 Jay Gregory D Methods of detecting lubricin
CN101077887A (zh) * 2006-05-23 2007-11-28 中国医学科学院血液学研究所 人促造血细胞增殖的细胞因子及其制备方法和用途
UY30776A1 (es) 2006-12-21 2008-07-03 Medarex Inc Anticuerpos cd44
WO2008143816A1 (en) 2007-05-15 2008-11-27 Mucosal Therapeutics Compositions and methods for reducing friction between the surface of tendons or other soft tissues
US20090068247A1 (en) 2007-09-12 2009-03-12 Mucosal Therapeutics Biocompatible devices coated with a tribonectin and methods for their production
US20090104148A1 (en) 2007-09-18 2009-04-23 Jay Gregory D Treatment and prevention of joint disease
US20090191287A1 (en) 2008-01-29 2009-07-30 Johnson W Dudley Mitigation of Inflammation-Related Injuries
US8506944B2 (en) * 2008-05-07 2013-08-13 The Regents Of The University Of California Replenishment and enrichment of ocular surface lubrication
JP5508398B2 (ja) 2008-05-07 2014-05-28 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 眼の表面潤滑の治療的補充及び強化
WO2010083239A2 (en) * 2009-01-13 2010-07-22 Truitt Edward R Iii Therapeutic modulation of vaginal epithelium boundary lubrication
CA2762989C (en) * 2009-05-22 2021-04-13 Benjamin Sullivan Prg4 for treatment of oral cavity boundary lubrication disorders
US9107885B2 (en) 2009-08-13 2015-08-18 Lubris Llc PRG4 treatment for interstitial cystitis
ES2627103T3 (es) 2010-01-19 2017-07-26 Lubris Llc Composiciones de cuidado bucal y métodos
US20130116186A1 (en) 2011-10-04 2013-05-09 Rhode Island Hospital, A Lifespan Partner Lubricin injections to maintain cartilage health
EP2948553B1 (en) * 2013-01-25 2020-04-01 Baylor College Of Medicine A helper-dependent adenoviral gene therapy delivery and expression system
WO2015060935A1 (en) 2013-10-22 2015-04-30 Lubris, Llc Control of rheological properties of mixed hyaluronate/lubricin solutions
EP4062924A1 (en) 2013-11-26 2022-09-28 Lubris LLC Compositions and methods for inhibiting intercellular interactions
US20180161393A1 (en) 2015-01-26 2018-06-14 Lubris Llc Prg4 for treating gout and its symptoms
ES2808199T3 (es) 2015-01-26 2021-02-25 Lubris Llc Uso de PRG4 como un agente antiinflamatorio
HUE056409T2 (hu) 2015-05-19 2022-02-28 Lubris Llc PRG4 alkalmazása dinamikus látásélesség és magasabb rendû aberrációk javítására
US20170312335A1 (en) 2015-12-30 2017-11-02 Lubris Llc Topical use of prg4 for treatment of allergy and symptoms of inflammation

Also Published As

Publication number Publication date
TN2017000270A1 (en) 2018-10-19
SG10201809947UA (en) 2018-12-28
RU2017129880A3 (pt) 2019-08-22
US20210299214A1 (en) 2021-09-30
CN107847556B (zh) 2021-09-24
CN113908257A (zh) 2022-01-11
JP2020189878A (ja) 2020-11-26
AU2016211694A1 (en) 2017-08-31
ES2808199T3 (es) 2021-02-25
EA201791688A1 (ru) 2018-01-31
CN107847556A (zh) 2018-03-27
WO2016123123A1 (en) 2016-08-04
HK1247834A1 (zh) 2018-10-05
CL2018003302A1 (es) 2019-01-04
MA53108A (fr) 2021-05-12
EP3250221A1 (en) 2017-12-06
IL285553A (en) 2021-09-30
PH12017501323A1 (en) 2018-02-05
EA201791688A8 (ru) 2018-05-31
JP6758299B2 (ja) 2020-09-23
BR112017015310A8 (pt) 2021-02-23
ZA201705378B (en) 2020-11-25
EP3718559A1 (en) 2020-10-07
MX2017009723A (es) 2018-08-15
US11717557B2 (en) 2023-08-08
JP2018505867A (ja) 2018-03-01
RU2017129880A (ru) 2019-03-04
CA2972817A1 (en) 2016-08-04
KR20170123619A (ko) 2017-11-08
IL253596B (en) 2021-08-31
US20180015141A1 (en) 2018-01-18
JP7212653B2 (ja) 2023-01-25
AU2022200812A1 (en) 2022-02-24
US10967048B2 (en) 2021-04-06
EP3250221B1 (en) 2020-05-27
EA036291B1 (ru) 2020-10-22
SG11201705636SA (en) 2017-08-30
IL253596A0 (en) 2017-09-28
CL2017001893A1 (es) 2018-06-15
AU2016211694B2 (en) 2021-11-11

Similar Documents

Publication Publication Date Title
BR112017015310A2 (pt) uso de pgr4 como um agente anti-inflamatório
SV2018005610A (es) Derivados de oxopiridina sustituidos
PH12018500586A1 (en) Farnesoid x receptor agonists and uses thereof
DOP2015000246A (es) Derivados de oxopiridina sustituida y usos de los mismos en el tratamiento de trastornos cardiovasculares
NI201600071A (es) Compuestos de inhibidor de autotaxina
DOP2016000150A (es) Nuevas indazolcarboxamidas, procedimientos para su preparación, preparaciones farmacéuticas que las contienen, así como su uso para la preparación de medicamentos
BR112015015891A8 (pt) Composição farmacêutica de solução sólida, e, uso de uma composição farmacêutica
MX366317B (es) Composiciones y metodos para tratar la inflamacion cronica y las enfermedades inflamatorias.
MX2015016100A (es) Inhibidores de criopirina para prevenir y tratar la inflamacion.
EA201691808A8 (ru) Кортикостероидные композиции для местного применения
CL2015000039A1 (es) Derivados estra-1,3,5(10),16-tetraeno-3-sustituidos, preparaciones farmacéuticas que los comprenden y su uso en la preparación de medicamentos para tratar la endometriosis.
MX2015009045A (es) Composiciones y metodos para tratar el dolor severo.
NI201600070A (es) Inhibidores tetracíclicos de autotaxina
GT201700138A (es) Pirazolpiridinaminas
UY35344A (es) Oestra-1,3,5(10),16-tetraeno-3-carboxamidas
CR20150653A (es) Compuestos nuevos para el tratamiento del cáncer
BR112016015997A2 (pt) ?composições farmacêuticas que compreendem 15- hepe e métodos para tratar asma e distúrbios pulmonares com o uso das mesmas?
ECSP16086247A (es) (s)-pirlindole y sus sales farmacéuticamente aceptables para uso en medicina
CO2017002813A2 (es) Derivados estabilizados de adrenomedulina y uso de los mismos
BR112018069682A2 (pt) métodos de tratamento para doenças colestáticas e fibróticas
IT201600081379A1 (it) Composizione farmaceutica per uso nel trattamento delle patologie prostatiche.
BR112017014552A2 (pt) ?análogo de calcitonina, e, método para produzir uma diminuição nos triglicerídeos no fígado/redução de acúmulo de gordura no fígado?
CL2015001502A1 (es) Composición farmacéutica que comprende desloratadina y prendnisolona y uso de la misma.
GB2537783A (en) Methods and compositions used in treating inflammatory and autoimmune diseases
CO2018004803A2 (es) Compuestos oxa-diazaspiro que tienen actividad contra el dolor

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 8A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2759 DE 21/11/2023.